| ￥3500 | |
| Z06103-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 43.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-55 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of EPHA5, His, Mouse is greater than 95% as determined by SEC-HPLC. »
EPHA5, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The aim of the present study was to evaluate ephrin type-A receptor 5 (EphA5) expression and its clinicopathological significance in gastric cancer. Gastric cancer tissues were analyzed by immunohistochemistry. The association between EphA5 expression and clinicopathological parameters, human epidermal growth factor receptor 2 (HER2) status and Ki-67 proliferation index was statistically analyzed. |
| Synonyms | EHK-1; EK7; BSK; EHK1; HEK7; TYRO4; EphA5; Rek7; TYRO4HEK7CEK7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
